Press release
Pancreatic Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)
Key Takeaways from the Pancreatic Cancer Pipeline Report
* DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
* The leading Pancreatic Cancer Companies working in the market include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
* Promising Pancreatic Cancer Pipeline Therapies in the various stages of development include Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
* April 2024- Amgen- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 in Combination With Other Therapies in Subjects With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion. The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
* April 2024:- AstraZeneca- LYNPARZA Tablets 100 mg, 150mg General Drug Use-results Study in Patients on Maintenance Treatment After Platinum-based Chemotherapy for BRCA Mutated Curatively Unresectable Pancreas Cancer. To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic cancer under the actual post-marketing use of LYNPAZA.
* April 2024:- EBG MedAustron GmbH- Phase II Trial of Hypo-fractionated Highly Conformal Radiotherapy for Locally Advanced Pancreatic Carcinomas. This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.
* April 2024:- Radboud University Medical Center- Intratumoral Holmium Microspheres Brachytherapy for Patients with Pancreatic Cancer; a Single Center, Non-randomized, Feasibility Study in an Open Surgical Setting - the SLOTH1 Study. This is a feasibility study in which patients with pancreatic cancer are treated with intratumoral holmium microsphere injections.
Request a sample and discover the recent advances in Pancreatic Cancer Treatment Drugs @ Pancreatic Cancer Pipeline Report [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
In the Pancreatic Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pancreatic Cancer Overview
Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas - an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms.
Find out more about Pancreatic Cancer Therapeutics Assessment @ Pancreatic Cancer Preclinical and Discovery Stage Products [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pancreatic Cancer Emerging Drugs Profile
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Pancreatic Cancer Pipeline Therapeutics Assessment
There are approx. 290+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.
DelveInsight's Pancreatic Cancer Pipeline Report covers around 300+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Pancreatic Cancer Pipeline Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Learn more about the emerging Pancreatic Cancer Pipeline Therapies @ Pancreatic Cancer Clinical Trials Assessment [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pancreatic Cancer Pipeline Report
* Coverage- Global
* Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
* Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
Dive deep into rich insights for new drugs for Pancreatic Cancer Treatment, Visit @ Pancreatic Cancer Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Pancreatic Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pancreatic Cancer - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Pamrevlumab: FibroGen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Niraparib: Innovent Biologics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* CT041: CARsgen Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* ONC 212: Oncoceutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pancreatic Cancer Key Companies
* Pancreatic Cancer Key Products
* Pancreatic Cancer- Unmet Needs
* Pancreatic Cancer- Market Drivers and Barriers
* Pancreatic Cancer- Future Perspectives and Conclusion
* Pancreatic Cancer Analyst Views
* Pancreatic Cancer Key Companies
* Appendix
For further information on the Pancreatic Cancer Pipeline therapeutics, reach out to Pancreatic Cancer Unmet Needs and Analyst Views [https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pancreatic-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here
News-ID: 3487983 • Views: …
More Releases from ABNewswire
Vinyl Fence Installation in Woodbury, NJ - Deptford Fence Company Introduces Pre …
Deptford Fence Company announces enhanced vinyl fence installation services in Woodbury, NJ, offering durable, low-maintenance fencing options for local homeowners. The company introduces upgraded materials, improved installation methods, and expanded residential fencing solutions throughout Gloucester County.
Woodbury, NJ - Deptford Fence Company, a trusted name in South Jersey's fencing industry, announces the introduction of new premium vinyl fence installation in Woodbury, NJ to better serve local homeowners seeking durable, low-maintenance solutions.…
Las Vegas Towing Officially Rebrands from ARB Las Vegas
Las Vegas, NV - Las Vegas Towing [https://lasvegastowtruck.com/], a trusted leader in towing, roadside assistance, and vehicle management solutions, is proud to announce its official rebrand from ARB Las Vegas to Las Vegas Towing. This transition marks a significant milestone for the company as it continues to evolve, expand, and strengthen its commitment to delivering exceptional service to motorists, property owners, and business partners across the Las Vegas Valley.
Located at…
Sebanti Collection Announces Launch of New Online Shop and Embraces a Pivotal Di …
Sebanti Collection has officially launched its new online shop, marking a major move for the Montreal-based jewelry brand. The new website offers a seamless, modern shopping experience with a mobile-friendly interface, secure checkout, and high-quality visual storytelling. This digital expansion allows customers worldwide to explore and purchase the brand's contemporary, high end gold jewelry collections.
Sebanti Collection, a Montreal-based fine jewellery brand celebrated for its thoughtful craftsmanship and personalized design services,…
New Specialty Beverage Brand Copper Kettle Coffee And Tea Emphasizes Mindful Con …
Copper Kettle Coffee And Tea, a new venture from Phoenix Retail and Marketing Services LLC, enters the specialty beverage market with a focus on transforming daily coffee and tea rituals into meaningful sensory experiences. The company's hand-selected beans and premium loose-leaf teas are designed to help consumers slow down and appreciate the complex flavors that characterize artisan beverages.
In an era defined by speed and convenience, Copper Kettle Coffee And Tea…
More Releases for Pancreatic
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Pancreatic Cancer Diagnostic Industry Market Size Be by 2025?
The sector dedicated to diagnosing pancreatic cancer has experienced significant upward momentum lately, projecting an expansion from a valuation of $4.24 billion in 2024 to $4.54 billion in 2025, reflecting a steady compound annual growth rate of…
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
